Skip to Content

Eaton Scientific Highlights International Potential for Tropine 3 as a Globally Accepted Non-Hormonal Treatment for Hot Flash Symptoms -- Menopause Hits Harder Outside the United States

BEVERLY HILLS, Calif., Sept. 26, 2012 /PRNewswire/ -- Eaton Scientific Systems, Ltd. ("Eaton" or the "Company") a wholly-owned subsidiary of Pristine Solutions, Inc. (OTCQB: PRTN) is pleased to highlight the increasing international potential of Tropine 3 for the non-hormonal treatment for pre-menopausal, peri-menopausal, and post-menopausal women experiencing hot flashes.

"Menopause affects women all over the world, but according to recent research it actually appears to affect women in Asia and Latin America at a dramatically younger age along with greater and longer symptom prevalence," stated Michael Borkowski, CEO of Eaton Scientific.  "With this in mind, we intend to develop Tropine 3 to take advantage of potential global marketing and distribution opportunities."

Recent scientific research has indicated that women in the United States and Europe reach menopause at a median age ranging from 50.1 to 51.4 years.  This same research study concluded that in Latin America the median age of menopause was 43.8 to 53 years, and in Asia from 42.1 to 49.5 years.  Other large research studies also concluded that the frequency of menopause symptoms range from 36–50% of women in North America, up to 45–69% in Latin America, 22–63% in Asia, and 74% in Europe.

The earlier onset of menopause and increased prevalence of menopause symptoms outside of North America represents an important strategic opportunity to expand Tropine 3 awareness on a global scale.  The Company could potentially enter into business arrangements with established drug distribution organizations to accomplish this.

About Pristine Solutions, Inc.

Pristine Solutions, Inc., through its wholly-owned subsidiary company, Eaton Scientific Systems, Ltd., holds the intellectual property and global marketing rights to Tropine 3, a patent pending novel indication of an existing FDA approved drug for the non-hormonal treatment of hot flashes in pre-menopausal, peri-menopausal, and post-menopausal women. The company is preparing for Phase 1 & 2 Clinical Trials with the goal of FDA approval of Tropine 3.

Forward-Looking Statements/Disclaimer

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  The words "forecast," "anticipate," "estimate," "project," "intend," "expect," "should," "believe," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pristine Solutions' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Pristine Solutions' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Pristine Solutions herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Pristine Solutions disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SOURCE Eaton Scientific Systems, Ltd.

CONTACT: Mark Bernhard, Capital Group Communications, +1-415-332-7200,

Posted: September 2012